Every material Form 8-K Bolt Biotherapeutics, Inc. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bolt Biotherapeutics acquired Prana Therapies through a stock-for-stock reverse merger and, concurrently, agreed to a $120 million upfront private placement of Series D preferred stock. After the financing, pre-transaction Bolt holders are expected to own about 6.9% of common stock, Prana holders about 51.7%, and private placement investors about 41.4%, so existing Bolt shareholders face substantial dilution and a major change in ownership.
Bolt issued 430,746 shares of common stock and 16,360.929 shares of Series D preferred stock to Prana stockholders; each preferred share converts into 1,000 common shares.
The private placement covers 13,995.311 Series D preferred shares for $120 million in upfront gross proceeds, with warrants for up to an additional $60 million upon exercise.
Conversion of the Series D preferred stock requires Bolt stockholder approval, and the private placement is expected to close on October 26, 2026.
The company expects the financing to fund operations into 2028; lead program PRA-216 has Phase 2 patient data expected from the second quarter through the fourth quarter of 2027.
Bolt Biotherapeutics entered into a second amendment to its Redwood City, California lease on October 1, 2026. The company paid the landlord $1.0 million, agreed the landlord may draw the existing $1.5 million letter of credit in full, and accepted an earlier lease expiration date that would require a $4.5 million termination payment upon a financing or other strategic transaction, which could weigh on shareholders' cash and results.
Company paid the landlord $1.0 million on signing the amendment
Landlord may draw the existing $1.5 million letter of credit in its entirety
Lease expiration accelerated to December 31, 2027, or earlier after a Corporate Transaction, with a $4.5 million termination payment due then
Company says ongoing rent and operating expense obligations are not significant; accounting effects are still being evaluated
Bolt Biotherapeutics reported second-quarter 2026 collaboration revenue of $5,000, down from $1.8 million a year earlier, while its net loss narrowed to $7.7 million from $8.6 million on lower research and general and administrative expenses. Cash, cash equivalents and marketable securities were $18.1 million at June 30, 2026, which the company expects to fund operations into the first quarter of 2027, and it said initial clinical data for its lead candidate BDC-4182 is expected with third-quarter 2026 results.
Collaboration revenue was $5,000 for Q2 2026, versus $1.8 million in Q2 2025
Net loss was $7.7 million, or $4.57 per share, versus $8.6 million, or $4.46 per share, a year earlier
Cash and marketable securities of $18.1 million as of June 30, 2026, expected to fund operations into 1Q 2027
Initial BDC-4182 clinical data expected with 3Q 2026 results; the rest of the pipeline is on hold
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bolt Biotherapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →